|
MechanismTubulin inhibitors |
|
|
|
|
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
拉洛他赛脂质微球注射液在晚期实体瘤患者中的人体安全性、耐受性、药代动力学研究Ⅰ期临床试验
[Translation] Phase I clinical trial of safety, tolerability, and pharmacokinetics of larotaxel lipid microsphere injection in patients with advanced solid tumors
评价拉洛他赛脂质微球注射液用于标准治疗不耐受或无效的晚期肿瘤患者的安全性和耐受性,探索最大耐受剂量(MTD)、剂量限制性毒性(DLT)及 II 期推荐剂量(RP2D),为后期临床试验制定给药方案提供依据。评价拉洛他赛脂质微球注射液用于标准治疗不耐受或无效的晚期肿瘤患者的药代动力学特征。
[Translation] To evaluate the safety and tolerability of larotaxel lipid microsphere injection in patients with advanced tumors who are intolerant or ineffective to standard treatment, explore the maximum tolerated dose (MTD), dose-limiting toxicity (DLT) and recommended dose for phase II (RP2D), and provide a basis for the formulation of dosing regimens for later clinical trials. To evaluate the pharmacokinetic characteristics of larotaxel lipid microsphere injection in patients with advanced tumors who are intolerant or ineffective to standard treatment.
100 Clinical Results associated with Wuxi Target Drug Research Co., Ltd.
0 Patents (Medical) associated with Wuxi Target Drug Research Co., Ltd.
100 Deals associated with Wuxi Target Drug Research Co., Ltd.
100 Translational Medicine associated with Wuxi Target Drug Research Co., Ltd.